Drug Product Science and Technology, Bristol-Myers Squibb Company , New Brunswick, NJ , USA.
Pharm Dev Technol. 2014 May;19(3):285-9. doi: 10.3109/10837450.2013.778869. Epub 2013 Mar 26.
The objective of the current work was to study an observed incompatibility between croscarmellose sodium and basic excipients in a tablet formulation. Significant dissolution slowdown was observed for alkaline tablet compositions of an acid-labile drug containing croscarmellose sodium (CCS) as a disintegrant. The severity of the dissolution slowdown was directly proportional to both the degree of alkalinity and the level of CCS in the tablet formulation. It is postulated that the ester cross-links in CCS were partially or fully hydrolyzed under basic conditions (pH values >9) forming by-products of increased water solubility. This increase in the level of water-soluble polymer can lead to the formation of a viscous barrier in the tablet upon moisture uptake, thus slowing down its dissolution. The dissolution slowdown was not observed for a similar alkaline tablet preparation containing crospovidone as a disintegrant.
本研究旨在探讨一种片剂配方中羧甲纤维素钠(CCS)与碱性辅料之间的不相容性。在含有 CCS(崩解剂)的酸不稳定药物的碱性片剂组成中,观察到显著的溶出减缓现象。溶出减缓的严重程度与片剂配方中碱性程度和 CCS 水平直接成正比。据推测,CCS 中的酯交联在碱性条件下(pH 值>9)部分或完全水解,形成水溶性增加的副产物。这种水溶性聚合物水平的增加可能会导致片剂在吸收水分时形成粘性屏障,从而减缓其溶解。对于含有交联聚维酮(崩解剂)的类似碱性片剂制剂,未观察到溶出减缓现象。